The disclosure provides compositions and methods for identifying a cancer patient, such as an esophageal cancer patient, suitable for a therapy that includes administration of a platinum drug and radiation pre-operatively, based on the expression level of an ERCC1 gene. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating the patients.
